Saturday, May 17, 2008

புர்கா போட்டால் மார்பகப் புற்றுநோய்

புர்கா போடுவதால் சூரிய வெளிச்சம் உடலில் படுவதில்லை. இவ்வாறு சூரிய வெளிச்சம் உடலில் படாமல் இருந்தால் விட்டமின் டி உடலில் உற்பத்தி ஆகாது.
விட்டமின் டி உற்பத்தி ஆகாமல் இருந்தால் மார்பக புற்றுநோய் வருகிறது.

Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients By Amanda Gardner
HealthDay Reporter
Fri May 16, 11:47 PM ET




FRIDAY, May 16 (HealthDay News) -- Women with breast cancer who have a vitamin D deficiency at the time of diagnosis are more likely to have a recurrence or to die from their disease, a new study shows.

ADVERTISEMENT

Surprisingly, the researchers also found that only 24 percent of the patients had adequate levels of vitamin D when they were diagnosed.


"This study found that vitamin D deficiency is very common among women with breast cancer, and it suggests that vitamin D deficiency is linked to poorer outcomes in these women," Dr. Nancy Davidson, director of the breast cancer program at the Johns Hopkins Kimmel Cancer Center, said during a May 6 press conference. Davidson is president of the American Society of Clinical Oncology (ASCO).


Nevertheless, the evidence isn't strong enough to suggest women with breast cancer take more of the vitamin.


"It's premature to tell all women diagnosed with breast cancer that they should take vitamin D supplements over and above what's recommended for bone health," said study author Dr. Pamela Goodwin, a medical oncologist with Mount Sinai Hospital and a professor of medicine at the University of Toronto. "If you're a woman with breast cancer, it's probably worthwhile having vitamin D levels checked. If they're deficient, they should take more to get it in the range that we think is beneficial."


The optimal levels of vitamin D associated with breast cancer risk in this study do overlap with optimal levels for bone health, Goodwin added.


Prior research has suggested that vitamin D levels may be associated with breast cancer risk, an idea that is biologically plausible.


"We know from basic science studies that breast cancer cells have vitamin D receptors and can interact with vitamin D," explained Goodwin, who plans to present her findings at the ASCO annual meeting, being held from May 31-June 3, in Chicago.


There is, however, a lot of confusion about the different health benefits of vitamin D and, the authors said, daily allowance recommendations vary greatly around the world.


The study involved 512 women newly diagnosed with localized breast cancer (confined to the breast and arm pit) between 1989 and 1995. All participants had had blood taken at the time of diagnosis and had also filled out a questionnaire on diet. Vitamin D levels were measured by radioimmunoassay.


The women, whose age averaged about 50, were followed for just under 12 years. Of the total, 37.5 percent were deficient in vitamin D (the lowest levels), 38.5 percent had insufficient levels of vitamin D (not deficient but not quite healthy levels), and 24 percent had levels in the healthy range.


Women who were premenopausal, weighed more, had high insulin levels and had more aggressive tumors were all more likely to have low vitamin D levels.


"Fat tissue acts as a trap for vitamin D," Goodwin explained. "Levels were also lower in younger women, which was a bit of a surprise, until we realized older women were taking more supplements."


The risk of breast cancer spreading was almost double in women with deficient levels of vitamin D at diagnosis, compared with women whose levels were healthy, the researchers said.


The risk of dying of breast cancer was 75 percent higher in women with too-low levels of vitamin D versus women in the optimal range, they added.


However, there was no survival difference between women with healthy levels and insufficient levels. The data also suggested that there may be a small increased risk of metastasis or death if vitamin D levels are high, but not a statistically significant effect, Goodwin said.


"This suggests that there's a healthy level for vitamin D and, if you are deficient, you have an increased risk of metastasis, but if you go above [a certain point], your risk of death goes up again," Goodwin said.


Although it's not a firm conclusion, Goodwin added, the finding "is raising a red flag. It's probably not safe to take very high levels and get vitamin D levels up really high."

And the findings are consistent with another study which found that men with prostate cancer who took vitamin D died earlier than those taking a placebo.

More information

7 comments:

Anonymous said...

அரபியாவில் ஏராளமான பெண்களுக்கு மார்பகப் புற்றுநோய்.

இதுவா காரணம்?

எழில் said...

அனானி

அது சம்பந்தமான இணைப்பு ஏதேனும் தர இயலுமா?

நன்றி

Anonymous said...

எச்சரிக்கைக்கு நன்றி

Anonymous said...

எழில்
உங்கள் கவனத்துக்கு

http://www.springerlink.com/content/l3550127165h7028/


Abstract In the Kingdom of Saudi Arabia (KSA), hospital and population based statistics have shown that breast cancer has the highest crude frequency rate among Saudi women. The scarcity of reports about the disease in the KSA has been the impetus to this analysis about breast cancer in the eastem province of KSA. Data on female patients with invasive breast carcinoma seen at King Fahd Hospital of the University in the eastern province of KSA, were retrospectively reviewed. The analysis intended to examine the pattern of the disease and the outcome for patients. Between 1985 and 1995, 292 patients were identified. Their median age±SD (standard deviation) was 42±10.5 years. Most patients were younger than 50 years (78%) and were predominantly premenopausals (79%). Only 25 (9%) of patients had stage I cancer, whilst 130 (44%), 90 (30%), and 47 (16%) had stage II, III, and IV, respectively. Among patients with known axillary nodal status (242 patients), only 37% were node-negative whilst 32% and 31% had 1–3, and ≥4 positive nodes, respectively. Adjuvant chemotherapy and tamoxifen were commonly offered; nonetheless, other adjuvant modalities were rarely utilised. The median follow-up ±SD of all patients was 62.3±8.9 months: 152 patients (52%) were alive with no evidence of disease, 25 (9%) were alive with evidence of disease, and 115 (39%) were dead from breast cancer or its related complications. The median survival of the entire group was not obtained, but the 10-year projected survival was 55%. For stage I and II patients, 118 (76%) were alive with a projected 10-year actuarial survival of 64%. On the other hand, only 51 (57%) of patients with stage III disease were alive with a median survival of 41.5 months (95% Confidence interval (CI), 18.9 to 51.3). Patients with stage IV disease demonstrated a poor outcome with a median survival of 23.5 (95%, CI 12.2 to 31.4). Multivariate analyses were performed to explore the influence of independent variables on overall survival (OS) for patients with non-metastatic disease. Besides the expected adverse effect of disease progression, the favourable influence of adjuvant chemotherapy and tamoxifen prevailed. The amount of benefit gained from tamoxifen, however, was small. Similar analyses were undertaken to determine the influence of independent variables on progression-free survival (PFS). These analyses ascertained the adverse effects of advanced stage and the favourable impact of adjuvant chemotherapy. Breast cancer in the KSA has features that are distinctive from those of industrialised countries. Survival data, however, were comparable. The favourable influence of adjuvant chemotherapy was evident on both OS and PFS. Adjuvant tamoxifen, however, had little effect. Due to its infrequent use, the role of other adjuvant modalities could not be asserted.
Keywords breast - cancer - Kingdom of Saudi Arabia

எழில் said...

நன்றி அனானி
உங்கள் இணைப்பு உண்மையிலேயே சிறப்பான ஆதாரத்தை தந்துள்ளது

Anonymous said...

அவ்வளவு வெயில் இருக்கும் நாட்டில் பெண்களை புர்கா போடவைத்து அவர்களுக்கு மார்பக புற்றுநோய்கொடுக்கும் மத வெறியை என்ன சொல்வது?

Anonymous said...

Thanks for the post